Avant Immunotherapeutics’s Partner, GlaxoSmithKline, Files Rotarix(R) Application for U.S. Marketing Approval with the FDA

NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics (Nasdaq: AVAN) today announced that its partner, GlaxoSmithKline (GSK) Biologicals, has filed a marketing application for the Rotarix® vaccine with the United States Food and Drug Administration (FDA). Rotarix® is a two-dose rotavirus vaccine given to children for the prevention of gastroenteritis caused by rotavirus.
MORE ON THIS TOPIC